"Lamivudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
| Descriptor ID |
D019259
|
| MeSH Number(s) |
D03.383.742.680.245.500.950.500 D13.570.230.329.950.500 D13.570.230.500.925.500 D13.570.685.245.500.950.500
|
| Concept/Terms |
Lamivudine- Lamivudine
- 3TC
- 2',3'-Dideoxy-3'-thiacytidine
- 2',3' Dideoxy 3' thiacytidine
|
Below are MeSH descriptors whose meaning is more general than "Lamivudine".
Below are MeSH descriptors whose meaning is more specific than "Lamivudine".
This graph shows the total number of publications written about "Lamivudine" by people in this website by year, and whether "Lamivudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lamivudine" by people in Profiles.
-
Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. J Antimicrob Chemother. 2024 02 01; 79(2):370-374.
-
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. AIDS. 2023 03 01; 37(3):413-421.
-
Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States. AIDS Res Ther. 2021 09 06; 18(1):57.
-
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection. Expert Opin Drug Metab Toxicol. 2018 Aug; 14(8):773-779.
-
Safety of zidovudine dose reduction in treatment-na?ve HIV infected patients. A randomized controlled study (MiniZID). HIV Med. 2016 Mar; 17(3):206-15.
-
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul; 14(7):572-80.
-
Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin North Am. 2006 Jun; 35(2):425-61, x.
-
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005 May 17; 142(10):821-31.
-
Evolving approaches to the treatment of chronic hepatitis B virus infection in children. J Clin Gastroenterol. 2005 Jan; 39(1):7-9.
-
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002 Sep; 123(3):719-27.